Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

• Egile Nagusiak: N. A. Avxentyev (Egilea), I. I. Andreyashkina (Egilea), E. V. Artamonova (Egilea), L. V. Bolotina (Egilea), E. I. Kovalenko (Egilea), N. N. Sisigina (Egilea)
• Formatua: Liburua
• Argitaratua: ABV-press, 2024-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

At present, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib, ribociclib, and abemaciclib are widely used for the first-line treatment of locally advanced or metastatic breast cancer. However, direct comparisons of these treatment options in randomized studies have not been co...